Managing CA-MRSA infections: Current and emerging options

Infections in Medicine

Volumn 26, Issue 2, 2009, Pages 49-58

  Raygada, Jose L ^b   Levine, Donald P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Daptomycin resistance; Infection control; Methicillin resistant Staphylococcus aureus (MRSA); Skin and soft tissue infections (SSTIs)

Indexed keywords

AZTREONAM; BACITRACIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEFTOBIPROLE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; NEOMYCIN; POLYMYXIN; PSEUDOMONIC ACID; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANEMIA; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY; COMMUNITY ACQUIRED PNEUMONIA; CONJUNCTIVITIS; CORNEA ULCER; DIAGNOSTIC PROCEDURE; DIARRHEA; ENDOCARDITIS; ENDOPHTHALMITIS; EPIDEMIC MENINGITIS; EYE INFECTION; FOLLICULITIS; FOOT DISEASE; FURUNCULOSIS; GASTROINTESTINAL INFECTION; HEMATOLOGIC DISEASE; HUMAN; IMPETIGO; INFECTION CONTROL; LID ABSCESS; LYMPHADENITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; NAUSEA; NECROTIZING FASCIITIS; NEUTROPENIA; ORBIT CELLULITIS; OSTEOMYELITIS; OTITIS MEDIA; PHOTOSENSITIVITY; PHYSICIAN; PYOMYOSITIS; RASH; REVIEW; RISK; RISK FACTOR; SEPSIS; SINUSITIS; SKIN ABSCESS; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VOMITING;

EID: 69549088824     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Crawford SE, Boyle-Vavra S, Daum RS. Community associated methicillin-resistant Staphylococcus aureus. In: Scheld WM, Hooper DC, Hughes JM, eds. Emerging Infections. Vol 7. Washington, DC: ASM Press; 2007:153-179.
2. Van Belkum A, Verbrugh H. 40 years of methicillin resistant Staphylococcus aureus. BMJ. 2001;323:644-645.
3. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus [published correction appears in N Engl J Med. 2007;357:1357]. N Engl J Med. 2007;357:380-390.
4. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR. 1999;48:707-710.
5. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. MMWR. 2003;52:88.
6. Fridkin SK, Hageman JC, Morrison M, et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities [published correction appears in N Engl J Med. 2005;352:2362]. N Engl J Med. 2005;352:1436-1444.
7. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51:4044-4048. (Pubitemid 350057804)
8. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445-1453. (Pubitemid 40471452)
9. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43:953-960. (Pubitemid 44631092)
10. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-2004 influenza season. Emerg Infect Dis. 2006;12:894-899.
11. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza in Louisiana and Georgia, December 2006-January 2007. MMWR. 2007;56:325-329.
12. Millar BC, Prendergast BD, Moore JE. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. J Antimicrob Chemother. 2008;61:1-7.
13. Marcotte AL, Trzeciak MA. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen in orthopaedics. J Am Acad Orthop Surg. 2008;16:98-106.
14. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353:1245-1251.
15. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics. 2005;115:642-648. (Pubitemid 43378904)
16. Guss J, Kazahaya K. Antibiotic-resistant Staphylococcus aureus in community-acquired pediatric neck abscesses. Int J Pediatr Otorhinolaryngol. 2007;71:943-948.
17. Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:322-345.
18. Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg. 2005;131:782-784. (Pubitemid 41366090)
19. Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope. 2006;116:288-291. (Pubitemid 44383940)
20. Jones TF, Kellum ME, Porter SS, et al. An outbreak of community-acquired foodbome illness caused by methicillin-resistant Staphylococcus aureus. Emerg Infect Dis. 2002;8:82-84.
21. Swartz MN. Clinical practice. Cellulitis. N Engl J Med. 2004;350:904-912.
22. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002;21:530-534. (Pubitemid 34625834)
23. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicob Agents. 2006;27:87-96. (Pubitemid 43138839)
24. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40:1429-1434. (Pubitemid 40628630)
25. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481-1490. (Pubitemid 34553708)
26. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol. 2004;50:854-858. (Pubitemid 38685764)
27. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
28. Sakoulas G, Moise-Broder P, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398-2402. (Pubitemid 38747480)
29. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-3886. (Pubitemid 44737223)
30. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330-1336.
31. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-451.
32. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46:668-674.
33. Arbeit RD, Maki D, Tally FP, et al; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
34. Fowler VG, Boucher HW, Corey GR, et al; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
35. Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis. 2003;22:372-373. (Pubitemid 36836624)
36. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis. 2005;37:946-949. (Pubitemid 43078115)
37. Ellis-Grosse EJ, Babinchak T, Dartois N, et al; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycinaztreonam. Clin Infect Dis. 2005;41(suppl 5):S341-S353.
38. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group [published correction appears in Am J Respir Crit Care Med. 2001;163:1759-1760]. Am J Respir Crit Care Med. 2000;161:753-762.
39. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52:37-44.
40. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril to vancomycin plus ceftazidime in the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647-655. (Pubitemid 351321545)
41. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis. 2008;61:103-109.
42. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40:374-380. (Pubitemid 40216504)
43. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-1415. (Pubitemid 41579981)
44. Yang XY, Li CR, Lou RH, et al. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol. 2007;56(pt 1):71-76.
45. Gauduchon V, Cozon G, Vandenecsh F. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis. 2004;189:346-353.
46. Weems JJ Jr, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50:2751-2755. (Pubitemid 44198697)
47. Rupp ME, Holley HP Jr, Lutz J. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:4249-4254. (Pubitemid 350209873)
48. Gonzáles V, Padilla E, Giménez M, et al. Rapid diagnosis of Staphylococcus aureus bacteremia using S. aureus PNA FISH. Eur J Clin Microbiol Infect Dis. 2004;23:396-398. (Pubitemid 38797723)
49. Forrest GN, Mehta S, Weekes E, et al. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother. 2006;58:154-158. (Pubitemid 44294999)
50. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45:601-608. (Pubitemid 47328642)
51. Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2008;27:433-437. (Pubitemid 351713065)
52. Diekema DJ, Climo M. Preventing MRSA infections: finding it is not enough. JAMA. 2008;299:1190-1192.
53. Center for Disease Control and Prevention. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the centers for disease control and prevention. http://www.cdc.gov/ncidod/dhqp/ pdf//ar/CAMRSA-ExpMtgStrategies.pdf. Accessed June 12, 2008.